Press release
Squamous Cell Carcinoma Pipeline Insights Report | DelveInsight
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Squamous Cell Carcinoma Treatment Landscape. Click here to read more @ Squamous Cell Carcinoma Pipeline Outlook [https://www.delveinsight.com/sample-request/squamous-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Squamous Cell Carcinoma Pipeline Report
* In January 2025:- Incyte Corporation:- This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced Cutaneous Squamous Cell Carcinoma. A Phase 2 Study Evaluating INCB099280 in Participants With Advanced Squamous Cell Carcinoma
* In January 2025:- Replimune Inc.:- RP1 is a selectively replication competent herpes simplex virus type 1(HSV-1). This is a Phase 1/2, open-label, multicenter repeat-dosing study of RP1 alone and in combination with nivolumab in patients with advanced malignancies, and contains both single agent dose escalation, dose expansion to include nivolumab, and the combination in multiple Phase 2 cohorts in individual tumor types.
* In January 2025:- Hoffmann-La Roche:- The purpose of this study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo in participants with unresectable esophageal squamous cell carcinoma (or those who are unable or unwilling to undergo surgery) and whose cancers have not progressed following definitive concurrent chemoradiotherapy (dCRT). Participants will be randomized in a 1:1:1 ratio to receive either tiragolumab plus atezolizumab (Arm A), tiragolumab matching placebo plus atezolizumab (Arm B), or double placebo (Arm C).
* DelveInsight's Squamous Cell Carcinoma pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Squamous Cell Carcinoma treatment.
* The leading Squamous Cell Carcinoma Companies such as Hookipa Pharma, Zenith Epigenetics, HiFiBiO, Nanobiotix, GSK, AstraZeneca, VCN Biosciences, Moderna Therapeutics, Exelixis, MacroGenics, Nykode Therapeutics, Tizona Therapeutics, Totus Medicines, Turnstone Biologics, Hoffmann-La Roche, Merus , and others.
* Promising Squamous Cell Carcinoma Therapies such as SI-B001, IFX-1, Afatinib 40 MG, Pembrolizumab Injection, MK-3475A, and others.
Discover groundbreaking developments in Squamous Cell Carcinoma therapies! Gain in-depth knowledge of key Squamous Cell Carcinoma clinical trials, emerging drugs, and market opportunities @ Squamous Cell Carcinoma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/squamous-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Squamous Cell Carcinoma Emerging Drugs Profile
* NBTXR-3: Nanobiotix
NBTXR3 is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with squamous cell carcinoma.
* mRNA-4157: Moderna Therapeutics
mRNA-4157 is an investigational personalized mRNA cancer vaccine, Merck's anti-PD-1 therapy, for the adjuvant treatment of patients with squamous cell carcinoma. The drug is currently being evaluated under Phase II/III clinical trial for the treatment of patients with squamous cell carcinoma.
* HB-200: Hookipa Pharma
HB-200 is HOOKIPA's lead oncology candidate engineered with the company's proprietary replicating arenaviral vector platform. HB-200 is an alternating 2-vector immunotherapy designed to focus the immune response against the encoded antigen. It comprises two single-vector compounds with arenaviral backbones based on LCMV and PICV. Both encode and express an identical E7E6 fusion protein, comprising well characterized tumor-specific antigens for HPV16+ cancers. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with squamous cell carcinoma.
* MCLA-158: Merus
MCLA-158 (also known as Petosemtamab) is a Biclonics low-fucose human full-length IgG1 antibody targeting the epidermal growth factor receptor (EGFR) and the leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5). The drug is designed to exhibit three independent mechanisms of action including inhibition of EGFR-dependent signaling, LGR5 binding leading to EGFR internalization and degradation in cancer cells, and enhanced antibody-dependent cell-mediated cytotoxicity and antibody-dependent cellular phagocytosis activity. The drug is currently being evaluated under Phase I/II clinical trial for the treatment of patients with squamous cell carcinoma.
* HFB-301001: HiFiBiO
HFB301001 is a novel fully human IgG1 class OX-40 agonistic antibody with an optimized pharmacological profile. In contrast to other anti-OX-40 antibodies, the agonistic activity of HFB301001 is further enhanced in the presence of the endogenous ligand OX-40L and does not result in reduced expression of OX-40 on T cells. The drug is currently being evaluated under Phase I clinical trial for the treatment of patients with squamous cell carcinoma.
Stay informed about the Squamous Cell Carcinoma pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Squamous Cell Carcinoma Unmet Needs [https://www.delveinsight.com/sample-request/squamous-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Squamous Cell Carcinoma Companies and Therapies
* Sichuan Baili Pharmaceutical Co., Ltd.: SI-B001
* InflaRx GmbH: IFX-1
* Merck Sharp & Dohme LLC: MK-3475A
* ImmunityBio Inc.- Aldoxorubicin HCl
* Incyte Corporation: INCB099280
Squamous Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
* Intravenous
* Subcutaneous
* Oral
* Intramuscular
Squamous Cell Carcinoma Products have been categorized under various Molecule types such as
* Monoclonal antibody
* Small molecule
* Peptide
Transform your understanding of the Squamous Cell Carcinoma Pipeline! See the latest progress in drug development and clinical research @ Squamous Cell Carcinoma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/squamous-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Squamous Cell Carcinoma Pipeline Report
* Coverage- Global
* Squamous Cell Carcinoma Companies- Hookipa Pharma, Zenith Epigenetics, HiFiBiO, Nanobiotix, GSK, AstraZeneca, VCN Biosciences, Moderna Therapeutics, Exelixis, MacroGenics, Nykode Therapeutics, Tizona Therapeutics, Totus Medicines, Turnstone Biologics, Hoffmann-La Roche, Merus, and others.
* Squamous Cell Carcinoma Therapies- SI-B001, IFX-1, Afatinib 40 MG, Pembrolizumab Injection, MK-3475A , and others.
* Squamous Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Squamous Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Table of Content
* Introduction
* Executive Summary
* Squamous Cell Carcinoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Squamous Cell Carcinoma- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* NBTXR-3: Nanobiotix
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* HB-200: Hookipa Pharma
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* HFB-301001: HiFiBiO
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Squamous Cell Carcinoma Key Companies
* Squamous Cell Carcinoma Key Products
* Squamous Cell Carcinoma- Unmet Needs
* Squamous Cell Carcinoma- Market Drivers and Barriers
* Squamous Cell Carcinoma- Future Perspectives and Conclusion
* Squamous Cell Carcinoma Analyst Views
* Squamous Cell Carcinoma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=squamous-cell-carcinoma-pipeline-insights-report-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/functional-dyspepsia-epidemiology-forecast-insight
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Squamous Cell Carcinoma Pipeline Insights Report | DelveInsight here
News-ID: 3837720 • Views: …
More Releases from ABNewswire
Ottawa Window Medics Reinforces Its "Restore, Don't Replace" Mission, Helping Ho …
Ottawa Window Medics, the region's trusted expert in window and door repair and restoration, today reaffirmed its commitment to transforming how homeowners address foggy, hazy, or moisture-damaged windows. The company's proven "Restore, Don't Replace" philosophy delivers substantial savings-often between 50% and 70% compared to full replacement-while extending the lifespan of existing windows and doors by as much as 20 additional years.
OTTAWA, ON - October 30, 2025 - Ottawa Window Medics,…
Super Daddy Universe Launches a Heartfelt Mission to Redefine Fatherhood
In a world that often celebrates superheroes with capes and powers, one brand has set out to celebrate a different kind of hero - Dad. Super Daddy Universe, a new and emotionally-driven eCommerce brand, is redefining the way fathers and children connect through play, creativity, and shared memories.
October 30, 2025 - In a world that often celebrates superheroes with capes and powers, one brand has set out to celebrate a…
Suncheon Joins Global Conservation Leaders as South Korea's "Ecological Capital" …
Suncheon has emerged as South Korea's "Ecological Capital," joining the world's conservation leaders with a vision that unites environmental restoration and healing tourism.
Image: https://www.abnewswire.com/upload/2025/10/308ee6f9bf4c9e478e007c6089e0f02a.jpg
(Image: Flocks of hooded cranes descend over the golden reeds of Suncheonman Bay. Each autumn, the wetlands turn into a sanctuary for migratory birds-and for visitors seeking to witness one of Asia's most poetic encounters between nature and life. Photo courtesy of Suncheon City)
SUNCHEON, South Korea -…
Travel Packages to Peru - Early Bird Deals by Travel Agency Book and Vamonos: Di …
Image: https://www.abnewswire.com/upload/2025/10/c7ea28cc5f1df5a8d8ec4b0c90df4d36.jpg
Book and Vamonos, a specialist in Peruvian travel, is thrilled to announce a 15% Early Bird Discount on all 2026 Peru travel packages and Peru tours, valid for bookings made by December 31, 2025. These designed itineraries are crafted to make exploring Peru's ancient wonders, vibrant culture, and unparalleled cuisine effortless, authentic, and truly unforgettable. By planning their trip with Book and Vamonos [https://www.bookandvamonos.com/?utm_source=abnewswire&utm_medium=pr&utm_campaign=press_october_home], travelers can travel more and…
More Releases for Squamous
Advanced Non-Squamous and Squamous NSCLC Market Size, Share, Emerging Trends, Fo …
According to a new report published by CoherentMI The advanced non-squamous and squamous NSCLC market is estimated to be valued at USD 10.89 Bn in 2024 and is expected to reach USD 16.58 Bn by 2031, growing at a compound annual growth rate (CAGR) of 7% from 2024 to 2031.
Most recent Report, named "Advanced Non-Squamous and Squamous NSCLC Market" Patterns, Offer, Size, Development, Opportunity and Forecast 2024-2031, by CoherentMI…
Best Statistical Advanced Non-Squamous and Squamous NSCLC Market Growth Set to S …
The latest competent intelligence report published by CoherentMI with the title "An Increase in Demand and Opportunities for Global Advanced Non-Squamous and Squamous NSCLC Market 2024" provides a sorted image of the Advanced Non-Squamous and Squamous NSCLC industry by analysis of research and information collected from various sources that have the ability to help the decision-makers in the worldwide market to play a significant role in making a gradual impact…
Squamous Cell Carcinoma Treatment Drugs, Pipeline Insights Report 2024
DelveInsight's, "Squamous Cell Carcinoma Pipeline Insight, 2024" report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Squamous Cell Carcinoma pipeline landscape. It covers the Squamous Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Squamous Cell Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our…
Squamous Cell Carcinoma Pipeline Drugs, FDA Approvals, and Companies 2024
DelveInsight's, "Squamous Cell Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Squamous Cell Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Pancreatic Ductal Adenocarcinoma Research.…
Advanced Non-Squamous & Squamous NSCLC Pipeline 2024 | FDA Approvals, Clinical T …
DelveInsight's, "Advanced Non-Squamous & Squamous NSCLC Pipeline Insight, 2024," report provides comprehensive insights about 9+ companies and 11+ pipeline drugs in Advanced Non-Squamous & Squamous NSCLC pipeline landscape. It covers the Advanced Non-Squamous & Squamous NSCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Non-Squamous & Squamous NSCLC therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the…
Advanced Non-squamous And Squamous NSCLC Pipeline Insight 2023 (Updated) | Compa …
DelveInsight's, "Advanced Non-Squamous & Squamous NSCLC Pipeline Insight 2023" report provides comprehensive insights about 9+ companies and 10+ pipeline drugs in Advanced Non-Squamous & Squamous NSCLC pipeline landscape. It covers the Advanced Non-Squamous & Squamous NSCLC pipeline drug profiles, including Advanced Non-Squamous & Squamous NSCLC clinical trials and nonclinical stage products. It also covers the Advanced Non-Squamous & Squamous NSCLC therapeutics assessment by product type, stage, route of administration, and…
